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osting by EAbstract The purpose of this study was to determine whether the levels of cystatin C and beta-2
microglobulin (B2M) are altered during the second trimester in the plasma of women who
subsequently develop preeclampsia.
Study design: We performed a case control study to compare the levels of cystatin C and B2M in
women in whom preeclampsia ultimately developed (n= 30) and in pregnant women who remained
normotensive throughout gestation (n= 60). The maternal plasma levels of cystatin C and B2M
were measured by enzyme-linked immunosorbent assay. Blood samples were collected between
15 and 20 weeks’ gestation for fetal aneuploidy screening and frozen at 20 C until assay after
groups had been selected.
Results: The median concentrations of cystatin C and B2M were signiﬁcantly higher in those who
subsequently developed preeclampsia when compared to those of normal pregnancy (median
668.6 ng/ml and 418.3 lg/ml vs 413.7 ng/ml and 321.2 lg/ml, respectively).
Conclusions: In this study, the maternal plasma levels of cystatin C and B2M were signiﬁcantly
elevated in pregnant women who subsequently developed preeclampsia as compared with335454; fax: +20 2 33370931.
H.M. Ragab).
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134 M.K. Farag et al.normotensive women. Alterations of these proteins antedate clinical symptoms and, thus, they may
be useful for early identiﬁcation of patients at the risk of developing preeclampsia.
ª 2011 Academy of Scientific Research & Technology. Production and hosting by Elsevier B.V.
All rights reserved.1. Introduction
Preeclampsia (PE) is a multisystem disorder that is speciﬁc to
human pregnancy. It is deﬁned as the association of
pregnancy-induced hypertension with proteinuria that occurs
after 20 weeks of gestation [31]. It is associated with high
maternal mortality and morbidity as well as the risk of
perinatal death, preterm birth, and intrauterine growth
restriction [24]. It has been reported to complicate 4–7% of
pregnancies worldwide [17].
Although the cause of preeclampsia remains elusive, the
origin of the condition is recognized as lying in the placenta.
This is because preeclampsia occurs only in the presence of
pregnancy and it resolves after delivery of the placenta [2].
Studies during the past decade have provided a better
understanding of the potential mechanisms responsible for
the pathogenesis of PE. The initiating event in PE appears to
be reduced uteroplacental perfusion as a result of abnormal
cytotrophoblast invasion of spiral arterioles [6].
It has been hypothesized that placental ischemia is an early
event, leading to the placental production of a soluble factor or
factors that cause maternal endothelial dysfunction resulting in
the clinical ﬁndings of hypertension and proteinuria.
Proteinuria and hypertension dominate the clinical picture,
because the chief target organ is the kidney (glomerular
endotheliosis) [11]. Thus, an altered renal function is an
essential component of the pathophysiology of the disorder.
Implantation of the placenta and vascular changes are
completed by 20–22 weeks of gestation. So although PE is
usually diagnosed in the second half of pregnancy, damage
has already occurred at an earlier stage of pregnancy [3].
b2 Microglobulin also known as B2M is a component of
MHC class I molecules [19]. Possessing an Ig-like domain,
B2M is non-covalently associated with a heavy chain of
HLA antigens [18].
Cystatin C is a nonglycosylated protein that belongs to the
cysteine protease inhibitors, cystatin superfamily. It is found in
virtually all tissues and body ﬂuids. It is a potent inhibitor of
lysosomal proteinases (enzymes from a special subunit of the
cell that break down proteins) and probably one of the most
important extracellular inhibitors of cysteine proteases (it
prevents the breakdown of proteins outside the cell by a
speciﬁc type of protein degrading [26,5]).
B2 microglobulin and cystatin C are freely ﬁltered by the
glomerulus and reabsorbed and catabolized by proximal
tubular cells. Therefore, their serum values could be a better
marker of glomerular ﬁltration rate (GFR) than serum
creatinine level [15]. Cystatin C values will be abnormally high
when GFR decreases to 88–95 ml/min per 1.73 m2 [14,13].
Some studies found B2M to be less adequate than cystatin C
as a GFR marker [7,4], but another did not show any
differences [14].
A previous study carried out by Kristensen and colleagues
[16] has reported that the plasma levels of cystatin C andbeta-2-microglobulin are signiﬁcantly elevated in preeclampsia
and that these low molecular mass proteins are useful markers
of renal impairment in preeclampsia. High levels of cystatin c
in PE might reﬂect placental ischemia [22].
The aim of this study is to determine whether a change in the
levels of cystatin C and beta-2-microglobulin could be detected
before the onset of PE, and thus, these two markers could be
used to predict the subsequent development of preeclampsia.2. Subjects and methods
This is a case-control study in which each woman in whom
preeclampsia ultimately developed was matched with 2 women
who remained normotensive throughout gestation. All women
were free of pre-existing hypertension, diabetes, renal disease
and gave birth to singletons. Written informed consent was
obtained from the women agreeing to participate in the study.
Maternal serum samples were originally collected between
15 and 20 weeks of gestation for the purposes of antenatal
screening for fetal aneuploidy and neural tube defects. This
screening program is available to all pregnant women
attending the Prenatal Diagnosis Clinic, at the National
Research Center. Serum samples were frozen at 20 C until
assay after groups have been selected.
The study group comprised 90 pregnant women. The ﬁrst
group (Group 1) consisted of 30 pregnant women who
developed preeclampsia. The second group (Group 2) consisted
of 60 women as controls, who were normotensive throughout
pregnancy and delivered infants who were appropriately sized.
Preeclampsia was deﬁned as either a systolic blood pressure
over 140 mm Hg or a diastolic blood pressure over 90 mm Hg
on two occasions, at least 6 h apart, occurring after 20 weeks
of gestation. Proteinuria was deﬁned as either >300 mg of
protein in a 24-h urine collection or two positive dipstick results
of at least 1+ (30 mg/dl) on two occasions 4-h apart, or urine
dipstick results of at least 2+ (100 mg/dl) with no evidence of
urinary tract infection. Blood pressure was measured after a
10 min rest, with the subject in the lying position.
All serum samples weremeasured in duplicates and themean
of the duplicates was used for the statistical analysis. Cystatin C
concentrationwasmeasured by a quantitative ELISA technique
using Quantikine human cystatin C immunoassay (R&D
Systems Europe Ltd.). The intra-assay and inter-assay
coefﬁcients of variation (CV) were less than 6.6 and 7, respec-
tively. Beta-2-microglobulin was measured using ORG 5 BM
immunoassay (Orgentec Diagnostica GmbH). The intra-assay
and inter-assay CV were less than 3.6 and 4.9, respectively.
2.1. Statistical analysis
The data were processed and analyzed using the program
(SPSS) statistical package for social sciences version II under
windows XP. Descriptive statistics were performed for
Table 1 Clinical characteristic of the study population.
Preeclampsia Controls P value
N= 30 N= 60
Maternal age (years) 28.8 ± 5.26 28.4 ± 4.77 NS
Gestation at delivery (weeks) 38.1 ± 0.88 39.8 ± 0.79 <0.001
Diastolic BP (mm Hg) 97.0 ± 4.22 71.5 ± 7.84 <0.0001
Systolic BP (mm Hg) 143.0 ± 5.87 112.0 ± 7.523 <0.0001
P value 60.0001 is highly signiﬁcant.
Table 2 Median levels of cystatin C and B2M in cases and controls.
Preeclampsia Controls P value
N= 30 N= 60
Cystatin C (ng/ml) 668.6 (71.7–1427.7) 413.7 (348.3–1177.1) <0.0001
B2M (lg/ml) 418.3 (150.4–570.0) 321.2 (98.5–548.1) <0.0001
P value 60.0001 is highly signiﬁcant.
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mean and standard deviation. Comparison of the means was
done using the paired ‘‘t’’ test with statistical signiﬁcance level
preset at 0.05 level [23].
3. Results
This study was conducted on 90 pregnant women attending the
Prenatal Diagnosis Clinic, at the National Research Center,
Cairo. All women were matched for age, gestational age at
sampling (15–20 weeks) and freezing time of samples. They
were divided into two groups according to the outcome:Figure 1 Plasma cystatin C (ng/ml) levels in cases and control.
Figure 2 Plasma B2M (lg/ml) levels in cases and control.Group I: Thirty pregnant women who later developed
preeclampsia after 20 weeks.
Group II: Sixty pregnantwomenwho remained normotensive
throughout the pregnancy.
The clinical characteristics of each group are presented in
Table 1. There were no signiﬁcant differences between the
two groups in terms of age or parity, but there was a signiﬁcant
difference in the gestation at delivery as women who developed
PE delivered early compared to normal pregnant women.
The plasma concentrations of cystatin C and B2M were
signiﬁcantly higher in women who developed preeclampsia
compared to normotensive women (668.6 ng/ml vs 413.7 ng/
ml, P 6 0.0001; 418.3 lg/ml vs 321.2 lg/ml, P 6 0.0001,
respectively). Table 2 shows values of cystatin C and B2M in
samples taken before 20 weeks. Fig. 1 shows plasma cystatin
C ng/ml levels in cases and control. Fig. 2 shows plasma
B2M lg/ml levels in cases and control.4. Discussion
In this study we found signiﬁcantly the elevated levels of
cystatin C and B2M in the second trimester in the plasma of
women who subsequently developed preeclampsia compared
to normal pregnant women. We chose 15–20 weeks as the
gestation for screening, because this is emerging as the visit at
which the biochemical testing for chromosomal and other
defects is carried out. Cystatin C and B2M are low molecular
weight proteins produced by all nucleated cells at a constant
rate. They are freely ﬁltered by the glomerulus and reabsorbed
and catabolized by proximal tubular cells [25,21]. Cystatin C is a
cysteine protease inhibitor with a molecular mass of 13 kDa [7].
Serum cystatin C concentration is reported to be unaffected by
muscle mass, age, inﬂammation, fever, or exogenous agents
[29]. However, there are reports that the thyroid function has
an impact on cystatin C concentrations [30]. The protein B2M
is an 11.7 kDa nonglycosylated polypeptide composed of 99
amino acids. Increased plasma levels of B2M occur in a variety
of autoimmune illnesses, infectious or inﬂammatory process,
and proliferative syndromes [14,10].
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target organ is the maternal endothelium [12]. Preeclampsia is
considered the most common glomerular disease in the world
[27]. Its etiology and pathogenesis remain poorly understood. It
is characterized by the new-onset hypertension and proteinuria,
in association with a characteristic glomerular lesion
‘‘endotheliosis’’. Glomerular endotheliosis is a characteristic
lesion found in renal biopsies of preeclamptic women, it
represents a speciﬁc variant of thrombotic microangiopathy
and has been considered as the hallmark of PE [9].
Hypertension has been attributed to an excess of
vasoconstrictor over vasodilator inﬂuences in the systemic
circulation. A parallel imbalance in the renal circulation would
be expected to lower the glomerular perfusion rate. Limited
glomerular ultraﬁltration capacity caused by endotheliosis in
combination with glomerular underperfusion, results in
depression of the glomerular ﬁltration rate (GFR) [27].
A study concerning serum levels of B2M in PE and normal
pregnancywas published byNoyan et al. [20]. These investigators
have found serum B2M concentrations to be signiﬁcantly
elevated inpreeclampticpatients comparedwithnormal pregnant
women, while no difference was found in B2M levels in
normotensive pregnancy compared with non-pregnant women.
Our data regarding both cystatin C and B2M levels are
consistent with the previous studies of Thilaganathan et al.
[28] and Saleh et al. [22]. Kristensen et al. [16] found the
elevated plasma concentrations of cystatin C and B2M in
patients with preeclampsia at the time of diagnosis, and,
both were displaying a similar diagnostic performance for
diagnosing preeclampsia. Although other studies found that
B2M concentrations were not predictive of the development of
preeclampsia [8,1].
Accurate prediction of PE is important for identifying those
women who require more intensive monitoring, permitting
earlier recognition and intervention to those at risk, thus
improving the maternal and fetal outcomes.
Thus, the ability to predict early in pregnancy those women
at high risk for PE might lead to decreased maternal and fetal
morbidity and mortality.
5. Conclusion
Our results showed that cystatin C and B2M levels were
increased in the second trimester plasma of women who
subsequently developed preeclampsia compared to normal
pregnant women. Although cystatin C and B2M may be
potential markers for predicting preeclampsia, further large
scale studies are essential to determine their usefulness.
Limitationsof the studyare the small sample size.Furthermore,
the population of the study was entirely Egyptian, thus, further
work is needed to determine whether levels of these biochemical
markers differ among different ethnic groups.
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